Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 13/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 4/20 | 0.32 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.30 |
| ▸ | ADAMTS1 | Q9UHI8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23745302 | 1.00 | ADAMTS5 (0.35) | ADAMTS5ADAM17MMP2ADAMTS4MMP13 | |
| SCHEMBL21424833 | 1.00 | ADAMTS5 (0.35) | ADAMTS5ADAM17MMP2ADAMTS4MMP13 | |
| SCHEMBL23901406 | 0.82 | ADAMTS4 (0.35) | ADAMTS5ADAMTS4 | |
| SCHEMBL22201074 | 0.79 | PLA2G10 (0.32) | ADAMTS5ADAM17MMP2ADAMTS4MMP13 | |
| SCHEMBL17871293 | 0.74 | ADAMTS5 (0.56) | ADAMTS5ADAM17MMP2ADAMTS4MMP13 | |
| SCHEMBL17884769 | 0.74 | ADAMTS5 (0.56) | ADAMTS5ADAM17MMP2ADAMTS4MMP13 | |
| SCHEMBL23745423 | 0.74 | ADAMTS5 (0.44) | ADAMTS5ADAM17MMP2ADAMTS4MMP13 | |
| SCHEMBL21473425 | 0.72 | TDP1 (0.32) | — | |
| SCHEMBL19996680 | 0.72 | TDP1 (0.32) | — | |
| SCHEMBL23384986 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | GALAPAGOS NV (BE) | 2020-11-10 | — | — | US | disclosed |
| US-20190315719-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315719-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | ADAMTS5, ADAMTS4, ADAMTS1 | ADAMTS5 1/4885ADAM17 10/4885MMP2 35/4885 |
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | ADAMTS5, ADAMTS4, ADAMTS1 | ADAMTS5 1/4885ADAM17 10/4885MMP2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.